Iskandar M, Xiao Barbero M, Jaber M, Chen R, Gomez-Guevara R, Cruz E
Cancers (Basel). 2025; 17(2).
PMID: 39858038
PMC: 11764024.
DOI: 10.3390/cancers17020257.
Jones-Weinert C, Mainz L, Karlseder J
Nat Rev Mol Cell Biol. 2024; .
PMID: 39614014
DOI: 10.1038/s41580-024-00800-5.
Zhou C, Yang Y, Shen L, Wang L, Zhang J, Wu X
BMC Cancer. 2024; 24(1):1059.
PMID: 39192222
PMC: 11350973.
DOI: 10.1186/s12885-024-12833-2.
Kouroukli A, Rajaram N, Bashtrykov P, Kretzmer H, Siebert R, Jeltsch A
Clin Epigenetics. 2023; 15(1):183.
PMID: 37993930
PMC: 10666398.
DOI: 10.1186/s13148-023-01599-2.
Brik A, Wichert K, Weber D, Szafranski K, Rozynek P, Meier S
BMC Res Notes. 2023; 16(1):279.
PMID: 37858127
PMC: 10585721.
DOI: 10.1186/s13104-023-06566-x.
Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA).
Ali J, Walter M
Cancer Cell Int. 2023; 23(1):197.
PMID: 37679807
PMC: 10483736.
DOI: 10.1186/s12935-023-03041-2.
Regulation and clinical potential of telomerase reverse transcriptase (TERT/hTERT) in breast cancer.
Yang R, Han Y, Guan X, Hong Y, Meng J, Ding S
Cell Commun Signal. 2023; 21(1):218.
PMID: 37612721
PMC: 10463831.
DOI: 10.1186/s12964-023-01244-8.
Association of the Telomerase Reverse Transcriptase rs10069690 Polymorphism with the Risk, Age at Onset and Prognosis of Triple Negative Breast Cancer.
Zins K, Peka E, Miedl H, Ecker S, Abraham D, Schreiber M
Int J Mol Sci. 2023; 24(3).
PMID: 36768147
PMC: 9916321.
DOI: 10.3390/ijms24031825.
Genomic, epigenomic, and transcriptomic signatures for telomerase complex components: a pan-cancer analysis.
Wang J, Dai M, Xing X, Wang X, Qin X, Huang T
Mol Oncol. 2022; 17(1):150-172.
PMID: 36239411
PMC: 9812836.
DOI: 10.1002/1878-0261.13324.
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen E, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E
J Transl Med. 2022; 20(1):419.
PMID: 36089578
PMC: 9465869.
DOI: 10.1186/s12967-022-03624-z.
Methylation of Subtelomeric Chromatin Modifies the Expression of the lncRNA TERRA, Disturbing Telomere Homeostasis.
Oliva-Rico D, Fabian-Morales E, Caceres-Gutierrez R, Gudino A, Cisneros-Soberanis F, Dominguez J
Int J Mol Sci. 2022; 23(6).
PMID: 35328692
PMC: 8955364.
DOI: 10.3390/ijms23063271.
DNA Methylation Analysis Identifies a Biomarker for Retinoic Acid-Induced Repression in Breast Cancer Cell Lines.
Nguyen E, Richerolle A, Sanchez-Bellver J, Varennes J, Segal-Bendirdjian E
Biomedicines. 2022; 10(3).
PMID: 35327497
PMC: 8945736.
DOI: 10.3390/biomedicines10030695.
Integrated evaluation of telomerase activation and telomere maintenance across cancer cell lines.
Hu K, Ghandi M, Huang F
Elife. 2021; 10.
PMID: 34486523
PMC: 8530513.
DOI: 10.7554/eLife.66198.
Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma.
Arakawa F, Miyoshi H, Yoshida N, Nakashima K, Watatani Y, Furuta T
Cancer Med. 2021; 10(19):6786-6794.
PMID: 34477310
PMC: 8495278.
DOI: 10.1002/cam4.4200.
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.
Ellingsen E, Mangsbo S, Hovig E, Gaudernack G
Front Immunol. 2021; 12:682492.
PMID: 34290704
PMC: 8288190.
DOI: 10.3389/fimmu.2021.682492.
Shelterin complex gene: Prognosis and therapeutic vulnerability in cancer.
Bhari V, Kumar D, Kumar S, Mishra R
Biochem Biophys Rep. 2021; 26:100937.
PMID: 33553693
PMC: 7859307.
DOI: 10.1016/j.bbrep.2021.100937.
A Novel Liquid Biopsy Strategy to Detect Small Amounts of Cancer Cells Using Cancer-Specific Replication Adenoviruses.
Takakura M, Takata E, Sasagawa T
J Clin Med. 2020; 9(12).
PMID: 33327605
PMC: 7765046.
DOI: 10.3390/jcm9124044.
Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E.
Song Y, Park Y
Endocrinol Metab (Seoul). 2020; 35(3):515-525.
PMID: 32981294
PMC: 7520576.
DOI: 10.3803/EnM.2020.304.
Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.
McKelvey B, Umbricht C, Zeiger M
Front Endocrinol (Lausanne). 2020; 11:485.
PMID: 32849278
PMC: 7412884.
DOI: 10.3389/fendo.2020.00485.
TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.
Li H, Li J, Zhang C, Zhang C, Wang H
Cancer Med. 2020; 9(19):7151-7160.
PMID: 32810393
PMC: 7541140.
DOI: 10.1002/cam4.3376.